Breast Cancer: Ipatasertib + Tecentriq + Paclitaxel
Breast Cancer: Ipatasertib + Tecentriq + Paclitaxel
Medical Supporter — Мэдээллийн мэдэгдэл
Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.
Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee B-66 Travel Service Provider License No. 35, Fukuoka Prefecture, Japan Medical Device Sales and Lease Management, Japan
Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee B-66 Travel Service Provider License No. 35, Fukuoka Prefecture, Japan Medical Device Sales and Lease Management, Japan
(Breast Cancer) Ipatasertib + Tecentriq + Paclitaxel
Ipatasertib + Tecentriq + chemotherapy as first-line treatment for triple-negative breast cancer achieves an objective response rate of 73%, unaffected by PD-L1 status and genetic factors.
On April 1, 2019, Roche announced Phase I clinical trial results for oral AKT inhibitor Ipatasertib + Tecentriq + chemotherapy (paclitaxel) at the American Association for Cancer Research conference (AACR 2019).
For previously untreated patients with locally advanced or metastatic triple-negative breast cancer, this study assessed the safety and efficacy of this therapeutic combination. The response rate was unaffected by PD-L1 status, PI3KCA/AKT1/PTEN gene mutations.
Additionally, the most common adverse effects observed in most patients were: diarrhea at 19%, and skin itching and desquamation at 27%.
Based on Phase I clinical trial results, this therapeutic approach demonstrated an objective response rate of 73% in triple-negative breast cancer, showing promising efficacy.
Data Source: https://www.roche.com/media/releases/med-cor-2019-04-01.htm
https://www.roche.com/media/releases/med-cor-2019-04-01.htm
Copyright© 2015 Shingihou Co., Ltd. All rights reserved.
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?
Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5